HomeREGULATORY
REGULATORY

AZ’s PD-L1 Inhibitor Durvalumab Up for MHLW Panel Review on April 25
(Apr.13.2018)

A key health ministry panel will discuss on April 25 the approval of AstraZeneca’s PD-L1 inhibitor durvalumab for the treatment of non-small cell lung cancer (NSCLC). It is expected to pick up official approval by the end of June if all goes well ...
(LOG IN FOR FULL STORY)